Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics is a clinical-stage biotechnology and medical device development company that has a strong proprietary platform technology called PermaFusion, which enhances drug performance. With their ongoing clinical study for their lead program GX-03 in moderate-to-severe eczema showing potential and a favorable real-world tolerability record, the company has secured a path to advance its program without solely relying on immediate common equity raises. Additionally, their newly announced loan agreement with Avenue Venture for up to $25M, combined with their rapidly advancing pipeline, positions the company for potential growth and success in the near future.

Bears say

Turn Therapeutics is a clinical-stage biotechnology and medical device development company that is highly dependent on the success of its proprietary platform technology, PermaFusion. Unfortunately, the company has faced numerous challenges in recent clinical studies, leading to a delay in potential market approval. Additionally, the company's potential market, patients with moderate-to-severe eczema, is limited compared to other chronic inflammatory diseases, making it difficult for Turn to achieve significant revenue growth.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.